Digital medical services platform Teladoc Health (NYSE:TDOC) reported revenue ahead of Wall Street’s expectations in Q3 CY2024, but sales fell 3% year on year to $640.5 million. On top of that, next quarter’s revenue guidance ($668.5 million at the midpoint) was surprisingly good and 5.4% above what analysts were expecting. Its GAAP loss of $0.19 per share was also 31.5% above analysts’ consensus estimates.
Is now the time to buy Teladoc? Find out in our full research report.
Teladoc (TDOC) Q3 CY2024 Highlights:
-
Revenue: $640.5 million vs analyst estimates of $631.9 million (1.4% beat)
-
EPS: -$0.19 vs analyst estimates of -$0.28 (31.5% beat)
-
EBITDA: $83.26 million vs analyst estimates of $82.44 million (small beat)
-
Revenue Guidance for Q4 CY2024 is $668.5 million at the midpoint, above analyst estimates of $634.3 million
-
Gross Margin (GAAP): 71.9%, in line with the same…
